Press Releases

  • VolitionRx to Initiate Study with University Hospital Bonn to Confirm NuQ® Test Accuracy in Lung Cancer

  • VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014

  • VolitionRx Enters Agreement with University of Oxford to Initiate Endometriosis Study

  • VolitionRx to Present at the SeeThruEquity Conference

  • VolitionRx Initiates Sponsorship of Two-time Cancer Survivor to Drive Awareness for the Importance of Early Cancer Detection

  • VolitionRx Presents Further Colorectal Cancer Data at 9th International Conference of Anticancer Research

  • VolitionRx Announces Prostate Cancer Collaboration with the University of Texas MD Anderson Cancer Center

  • VolitionRx NuQ(R) Blood Test Detects 84% of Colorectal Cancers; Including Both Early- and Later-stage Cancers

  • VolitionRx to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference

  • VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials